射频消融治疗肝肿瘤315例报告

目的总结1999年6月至2003年8月用射频消融（radiofrequency ablation，RFA）治疗315例肝肿瘤病人的病例资料，探索RFA治疗肝肿瘤近远期疗效。方法采用了一次定位、多点穿刺，RFA联合肝动脉栓塞（TAE）、选择性门静脉栓塞（SPVE）治疗直径5～13cm的大肝癌，及经皮经肺经膈肌RFA治疗膈顶部肝癌。结果总并发症发生率为5．1％，无一例住院期间死亡。AFP阳性的169例肝癌病人中，RFA后有124例（73．6％）明显降低，其中有95例（56．2％）转阴。半年生存率为89．5％，1年生存率为80．1％，18个月生存率为61．4％，24个月生存率为48．3％，〉36个月生存率为35．6％。结论采用TAE、SPVE及RFA一次定位多点穿刺法治疗无手术切除指征的中晚期（含大肝癌）的病人，疗效明显，总并发症发生率低。     

射频消融在肝肿瘤治疗中的并发症

射频消融(radiofrequency ablation，RFA)治疗是在超声、CT或其他影像学设备的引导下，将射频电极针插入肿瘤内，利用高频交流电对局部组织进行高温热凝固，从而达到杀灭肿瘤的目的。RFA是近年来肝肿瘤局部治疗方法中发展较快的方法之一，可经皮、经腹腔镜或开腹术中进行，具有创伤小、疗效高的特点。目前认为，RFA是一种相对安全有效的方法，尤其对于无法手术切除的肝脏肿瘤有很好的姑息治疗效果。近年来，随着RFA方法的广泛应用和治疗病例的     

射频消融治疗肝肿瘤的现状和展望

肝癌最有效的治疗方法是手术切除 ,但手术切除率仅为 2 0 %～ 30 %;对不能手术切除的肝癌则多采用以局部治疗为主的综合疗法[1] 。肝癌的局部治疗包括经肝动脉或门静脉的血管栓塞疗法和以无水酒精注射、冷冻、微波、激光、高强度聚焦超声以及射频消融 (ＲａｄｉｏＦｒｅｑｕｅｎｃｙＡｂｌａｔｉｏｎ ,ＲＦＡ)为主的间质消融疗法[2 ] 。由于肝癌的局部治疗损伤小、适应证宽、近期疗效明显 ,已广泛应用于肝癌的治疗 ;而ＲＦＡ疗法是当今应用最广、发展最快的肝癌间质消融方法[2 ] 。80年代中期 ,日本学者[3] 开始了射频消融疗法治疗肝肿瘤的…     

射频消融治疗老年肝脏肿瘤（附126例临床分析）

目的 探讨射频消融（radiofrequency ablation，RFA）治疗老年肝肿瘤患者的安全性。方法 对126例老年肝肿瘤患者进行了161次RFA治疗，临床观察治疗后其对机体的反应、并发症发生及防治情况。结果 并发症发生率7．1％（9／126），其中皮肤烧伤3例，胸腔积液2例，肝功能不全2例，结肠穿孔1例，皮下出血1例，无临床死亡病例。结论 射频消融治疗老年肝肿瘤是一种较安全的方法，对机体影响轻微。     

射频消融治疗肝癌

射频消融为目前国际上新兴的肝癌治疗手段 ,具有安全、微创、适应证广、并发症少的特点。本文就射频消融技术的基本原理、适应证与禁忌证、临床应用治疗效果及其并发症进行讨论。     

肝切除联合射频消融治疗中期肝癌

目的 探讨肝切除联合射频消融在中期肝癌治疗中的应用价值.方法 回顾性分析2008年10月-2011年11月,安徽省立医院肝脏外科采用肝切除联合射频消融治疗的中期肝癌患者19例,术前采用肝功能Child评分标准、吲哚菁绿排泄试验等方法对患者肝功能进行评估,术后7d结合肝功能各项指标对近期并发症进行评价,术后4周以血清甲胎蛋白、增强CT、超声造影检查为标准,对近期疗效进行评价,术后半年内每月行血清甲胎蛋白、增强CT、超声造影等检查1次,以后每2～3个月复诊1次.结果 术后7d全部病例均有不同程度的肝功能损害,但无肝性脑病及死亡病例的发生;术后4周残留病灶占全部病例的10.1％ (2/19),消融不全10.1％ (2/19);术后1年、2年生存率分别为83.2％、46.4％,平均生存时间22.23个月,中位生存时间24.87个月.结论 肝切除联合射频消融在中期肝癌的治疗中有重要的应用价值,适当的扩大了肝癌特别是中期肝癌手术探查的指征,最大限度的杀灭了肉眼可见的病灶.     

射频消融治疗肝肿瘤的现状及其临床地位的评价

射频消融（radiofrequency ablation，RFA）作为治疗肿瘤的新方法，在得到临床医生重视的同时，尽早界定RFA的评价和地位是临床应用的迫切需要，但其界定义不得不等待相当长的一段时间。国内外对肝肿瘤射频消融的基础研究和临床应用已经有13年的经验，相关的研究越来越多。本文纵览近年文献，概括与归纳射频治疗肝肿瘤技术的发展，适应证，临床疗效、预后、影响因素以及并发症，并对RFA与其它治疗方法进行比较。对其在肝肿瘤治疗领域中的地位，做出初步的评价。     

射频消融治疗老年肝脏肿瘤(附126例临床分析)

目的探讨射频消融(radiofrequency ablation,RFA)治疗老年肝肿瘤患者的安全性。方法对126例老年肝肿瘤患者进行了161次RFA治疗,临床观察治疗后其对机体的反应、并发症发生及防治情况。结果并发症发生率7.1%(9/126),其中皮肤烧伤3例,胸腔积液2例,肝功能不全2例,结肠穿孔1例,皮下出血1例,无临床死亡病例。结论射频消融治疗老年肝肿瘤是一种较安全的方法,对机体影响轻微。     

多电极射频消融治疗肝肿瘤浅析

多电极射频消融技术在上世纪90年代初作为一个较成熟的手段用于肝脏肿瘤,后引入国内,近5年来,各应用单位已有了一定临床应用的实践积累,编出一组初步总结以供参考。这一技术的应用为肝癌的综合治疗增强加了一个实用和有效的手段,它不仅可以满足不同病理状态下肝癌病人的治疗需要,而且在以手术切除肝癌为中心的综合治疗中可用以与其它介入手段相互补充和完善,在不可切除肝癌的病人以其介入途径、B超定位和引导,据情调节能量输入多弹头和可分次重复治疗,更显示它的实用价值。和任何应用手段一样,需要强调的是应紧紧根据对病人全身情况与局部病变的综合评估,作出治疗手段应用的合理选择。——编者     

射频消融治疗肝血管瘤100例分析

目的 总结射频消融（radiofrequency ablation,RFA）治疗肝血管瘤的临床经验。方法 回顾性分析新疆军区总医院2013年3月至2017年10月采用RFA治疗的100例共101个肝血管瘤结节的病例资料。对RFA治疗前后最大瘤体直径的变化及治疗后出血、血尿、肾功能损害等并发症情况进行统计分析。结果 101个结节中88个结节经RFA后完全毁损,完全毁损率87.1%;其中直径≤4 cm的血管瘤完全消融率92.1%（35/38）,直径＞4 cm的血管瘤完全消融率84.1%（53/63）。RFA术后1个月所有瘤体平均直径由从术前的（4.2±1.8） （2～11）cm降为术后的（2.1±1.8） （0～6）cm,差异有统计学意义（P=0.03）。一个血管瘤治疗前直径为11 cm,经RFA治疗后缩小54.5%。术后52%（52/100）的患者出现发热,体温37.5～38.5 ℃,物理降温后体温均可正常。未经抗生素处理,术后3～5 d后均未出现发热,未出现术后严重并发症。结论 射频消融治疗肝血管瘤安全、有效,特别是对于瘤体较小的血管瘤效果更明显。需要注意的是应该根据血管瘤的大小、局部毗邻关系及分布特点采用个体化的射频治疗方式。     

射频消融治疗肝脏肿瘤的初步观察

目的探讨射频消融治疗肝脏肿瘤的近期疗效、不良反应及其安全性。方法对我科2004年12月~2005年6月收治的肝脏肿瘤29例的临床资料进行回顾性分析,以治疗后症状是否减轻、病变区范围是否缩小和CT增强扫描时病变区是否有强化来评价治疗效果。结果本组29例均完成治疗。术后1~5个月随访,症状消失13例,症状减轻14例;CT检查证实瘤体体积缩小29%~87%,平均为57%。结论射频消融治疗肝脏肿瘤具有微创、有效、简单、安全和可重复等优点,是局部治疗肝脏肿瘤的有效方法之一。     

射频消融术辅助部分肝切除术治疗原发性肝癌的效果及复发率随访研究

目的探讨射频消融术辅助部分肝切除术治疗原发性肝癌的效果及复发率随访研究。方法以2013年3月~2015年10月我院肝胆外科收治的60例原发性肝癌为研究对象,随机数字表法将其均分为对照组及研究组各30例,对照组实施部分肝切除术治疗,研究组在对照组基础上另联合射频消融术辅助治疗,观察2组手术相关指标[手术时间、创面平均出血量、术后住院时间]、术前术后肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBIL)、谷草转氨酶(AST)]、并发症发生率及随访复发率。结果研究组手术时间、术后住院时间较对照组显著短,而创面平均出血量较对照组显著低,差异有统计学意义(P0.05);术前2组ALT、TBi L、AST相较无明显差异(P0.05);术后2组ALT、TBi L、AST较术前明显降低,且术后研究组各项指标的变化程度较对照组明显(P0.05);术后研究组并发症发生率、术后1年随访复发率较对照组显著低,差异有统计学意义(P0.05)。结论射频消融术在原发性肝癌患者部分肝切除术中有明显积极作用,符合现代无血肝切除的理念,具有术中出血量少、康复时间短、保护肝功能、术后并发症及复发率低的优势,有推广应用价值。     

Controlled study of inline radiofrequency ablation (ILRFA) assisted transection of ovine liver

BACKGROUND: Liver resection is now a standard treatment for primary and secondary hepatic tumors around the world. Intra-operative blood loss during liver resection is a major factor associated with morbidity and mortality. We have developed a new instrument using radiofrequency energy (ILRFA), which is intended to achieve coagulative ablation in a plane. This plane can then be cut through with a scalpel, ultrasonic dissector, or diathermy with minimal blood loss. MATERIALS AND METHODS: Five sheep were used in this non-recovery experiment. In these sheep we performed five liver resections with the ILRFA and five similar resections using diathermy and suturing as control. Blood loss was measured by determining the difference in the weights of dry sponges and blood stained sponges after resection. RESULTS: ILRFA was successful in achieving coagulative ablation in all cases to a width of 1 cm. The mean blood loss in ILRFA was 43.2 g (SD36) and 221.8 g (SD147) in the control group. The bleeding was significantly reduced in ILRFA group with a P value of 0.005. CONCLUSIONS: Bleeding remains an important complication of liver resection. To reduce bleeding during liver surgery, different techniques have been used. In this study, we have demonstrated that by using ILRFA we can perform liver resections in sheep with minimal blood loss.     

Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation--a clinical and histological examination

BACKGROUND: Radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) is an optional treatment for patients awaiting liver transplantation (LTX). The study evaluates the efficacy of RFA in the explanted liver and its effect on patient outcome. MATERIAL AND METHOD: Forty-seven patients underwent RFA and were listed for transplant between January 1998 and May 2003. The patients were divided into two groups: transplanted and non-transplanted. Both groups were evaluated in terms of tumor characteristics, recurrence, mortality rate, and time on the waiting list. The ablation sites in the explanted livers were examined for percentage of necrosis by Hematoxylin & Eosin (H&E) stain and by TUNEL stain. RESULTS: Transplantation was carried out in 35 patients (74.5%). Ten patients (21.3%) died before transplant or were removed from the wait list, while two patients (4.2%) are still listed. Mortality and tumor-related mortality were significantly higher in the non-transplanted group. The time spent on the waiting list was longer in the non-transplanted patients (350 vs. 186 d average, p = 0.0345). Thirty-eight ablation sites were examined in the explanted livers. The percentage of tumor necrosis by TUNEL staining was 19.6% higher than that reported by H&E staining. After TUNEL staining, 28 sites (73.7%) had more than 90% necrosis, eight sites (21.0%) had 50-90%, and two sites (5.3%) had less than 50% necrosis. CONCLUSIONS: RFA and LTX can be used successfully in HCC patients, and in most cases, tumor necrosis can be achieved with ultrasound-guided RFA. H&E stain tends to under-represent the amount of tumor necrosis on the ablation sites. Survival of RFA patients after LTX is excellent.     

Radiofrequency ablation for renal tumors: Our experience

Objectives:   To report our results of percutaneous radiofrequency ablation (RFA) for renal tumors and to assess predictors of therapeutic efficacy.
Methods:   Forty patients (median age 73 years) with renal tumors were treated with RFA under local or epidural anesthesia. All of them had high surgical risk or refused radical surgery. Tumors were punctured percutaneously using the Radionics Cool-tip RF System under computed tomography or ultrasonographic guidance. Median tumor diameter was 24 mm. After RFA, contrast-enhanced computed tomography or magnetic resonance imaging was performed within 1 month. Complete response (CR) was defined as no enhancement inside the tumor. Factors related to the outcome and to renal function were assessed.
Results:   Median follow up was 16 months. CR was observed in 34 cases (85.0%). A significant difference in CR rate was observed between tumors ≤30 mm and those >30 mm. Outcomes tended to be better for tumors in the mid to lower kidney, and those away from the renal hilum. Recurrence was observed in one case (2.9%), but a CR was obtained again by additional RFA. Out of a total of 77 RFA procedures, complications occurred in only three cases (3.9%), and conservative treatment was possible in all cases. Serum creatinine levels 3 months after RFA did not differ from those before RFA.
Conclusions:   Percutaneous RFA is a safe and effective treatment for small renal tumors in patients with high surgical risk or who refuse radical surgery.     

射频治疗肝癌对患者肝功能的影响

目的:探讨肝癌射频治疗对肝功能的影响.方法:32例经皮肝癌射频治疗患者,分为小肝癌组(<3 cm)、大肝癌组(3~10 cm)和巨大肝癌组(>10 cm).对所有患者分别于术前及术后3 d进行血肝功能指标检测.结果:肝癌射频治疗对肝功能的影响与肿瘤大小、是原发性还是转移性有关.肿瘤越大,射频治疗对肝功能的影响越大,表现为巨大肝癌组大于大肝癌组,后者大于小肝癌组;射频治疗对原发性肝癌患者肝功能的影响大于转移性肝癌患者.结论:肝癌射频治疗前患者肝功能最好,处于Child-Pugh A级或B级.对于肿瘤直径大于10 cm的巨大肝癌患者,为防止术后肝功能衰竭,可对患者行分次治疗.